TrialEuropean journal of nuclear medicine and molecular imaging2022

Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based

Anna Sundlöv et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.